A clinical trial comparing volrustomig against Keytruda was reported, alongside news that Union Investment is an AstraZeneca shareholder.
1 report, 1 independent
Updated Aug 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A clinical trial comparing volrustomig against Keytruda was reported, alongside news that Union Investment is an AstraZeneca shareholder.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.Sub-event
Volrustomig trial compared against Keytruda; Union Investment is an AstraZeneca shareholder.1 source
Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Cramer provided market sentiment and investment advice regarding company trials involving AstraZeneca and Trinity Industries.
- Both the Netherlands and AstraZeneca were discussed as potential undervalued international investments.
- AstraZeneca plans its largest manufacturing investment in Virginia, reported from Cambridge.